{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095073","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.392885+00:00","generated_at":"2026-05-31T10:01:40.423020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026","bullets":["Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.","Cash, equivalents and short-term investments $368.7M as of June 30, 2024; runway into H2 2026.","ANX005 (GBS) Phase 3 met endpoints; RWE topline data expected year-end 2024; BLA filing H1 2025.","ANX007 (GA) Phase 3 ARCHER II trial dosing initiated; topline data expected H2 2026.","ANX1502 oral C1s inhibitor bridging study to tablet completed; POC data in CAD expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095073","json":"https://secwatch.observer/filing/0000950170-24-095073.json","markdown":"https://secwatch.observer/filing/0000950170-24-095073.md","text":"https://secwatch.observer/filing/0000950170-24-095073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/0000950170-24-095073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000095017024095073/annx-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:01:40.423020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}